What is the appropriate evaluation and management of peripheral eosinophilia?

Evaluation and Management of Peripheral Eosinophilia

For any patient with peripheral eosinophilia, immediately assess for end-organ damage (cardiac, pulmonary, or neurologic symptoms) and obtain a detailed travel history focusing on helminth exposure, as these two factors determine urgency and initial management. 1

Immediate Risk Stratification

Urgent evaluation is mandatory for patients presenting with:

• Cardiac symptoms: chest pain, dyspnea, heart failure, or arrhythmias 1
• Pulmonary symptoms: persistent cough, wheezing, or infiltrates on imaging 1
• Neurologic symptoms: altered mental status, focal deficits, or peripheral neuropathy 1
• Absolute eosinophil count ≥5.0 × 10⁹/L at any time 1
• Persistent eosinophilia ≥1.5 × 10⁹/L for more than 3 months with any organ involvement 1

These patients require emergency assessment for eosinophil-mediated organ damage, which can progress to irreversible fibrosis even before symptoms appear. 1

Essential History Elements

Obtain the following specific details:

• Travel history: exact dates and locations of freshwater swimming in Africa/tropical regions, barefoot walking, consumption of raw or undercooked meat 2, 3
• Timing: onset of eosinophilia relative to travel (2–8 weeks suggests acute schistosomiasis) 2
• Medication review: start dates of all medications, particularly antibiotics (nitrofurantoin), as drugs are a frequent cause 1
• Immigration status: migrants from helminth-endemic regions have 19–80% prevalence of parasitic infection 1
• Immunosuppression: HIV status, planned immunosuppressive therapy (critical for Strongyloides risk) 2, 1
• Atopic history: asthma, allergic rhinitis, atopic dermatitis, food allergies (present in 50–80% of mild eosinophilia cases) 1
• GI symptoms: dysphagia or food impaction (suggests eosinophilic esophagitis) 1

Severity-Based Diagnostic Approach

Mild Eosinophilia (0.5–1.5 × 10⁹/L)

In non-travelers, allergic disorders and medications account for ~80% of cases. 1

In travelers or migrants, helminth infections explain 19–80% of cases and must be excluded first. 1

Initial workup:

• Three separate concentrated stool specimens for ova and parasites (not just one) 2, 3
• Strongyloides serology (higher sensitivity than stool microscopy for this pathogen) 2, 3
• Schistosomiasis serology if any freshwater exposure in endemic areas (Africa, Southeast Asia, South America, Arabian Peninsula) 2, 3
• HIV testing per BHIVA guidelines if risk factors present 2

For asymptomatic patients with negative initial testing:

• Consider empirical treatment with albendazole 400 mg single dose PLUS ivermectin 200 μg/kg single dose for those >24 months with travel to endemic regions 2, 3
• CRITICAL: Exclude Loa loa infection BEFORE ivermectin by checking blood film for microfilariae in patients from Central/West Africa, as ivermectin can cause fatal encephalopathy if Loa loa is present 2, 3
• Repeat treatment at 8 weeks to cover maturing worms 3

If parasitic workup negative:

• Optimize control of atopic conditions (asthma, rhinitis, eczema) 1
• Review and discontinue any potentially causative medications 1
• Monitor eosinophil count every 3–6 months 1

Moderate-to-Severe Eosinophilia (≥1.5 × 10⁹/L)

Allergy alone rarely produces counts ≥1.5 × 10⁹/L, so comprehensive infectious and hematologic workup is mandatory. 1

Complete laboratory panel:

• Complete blood count with differential 1
• Comprehensive metabolic panel, LDH, liver function tests 1
• Three concentrated stool specimens for ova/parasites 2, 3
• Strongyloides serology and culture 2, 3
• Schistosomiasis serology if indicated 2, 3
• Serum tryptase and vitamin B12 (elevated in PDGFRA-rearranged disorders) 1
• Total IgE (nonspecific but may suggest lymphocytic-variant HES) 1

Hematologic evaluation if eosinophilia persists >3 months after treating/excluding infectious causes:

• Peripheral blood smear review 1
• Bone marrow aspiration and biopsy with immunohistochemistry 1
• Conventional cytogenetics, FISH, and molecular testing for tyrosine kinase fusions (PDGFRA, PDGFRB, FGFR1) 1, 4
• Next-generation sequencing if conventional methods inconclusive 1
• Refer to hematology 1

Identification of PDGFRA/PDGFRB rearrangements is critical because these patients respond dramatically to imatinib 100–400 mg daily, achieving complete hematologic response within 1 month and cytogenetic response by 3 months. 1

Organ-Specific Evaluation

Cardiac Assessment (if troponin elevated or cardiac symptoms)

• Electrocardiogram 1
• Cardiac troponin and NT-proBNP 1
• Echocardiography 1
• Cardiac MRI to distinguish eosinophilic cardiac disease from other etiologies 1

Pulmonary Assessment (if respiratory symptoms or infiltrates)

• Chest X-ray (migratory infiltrates suggest Loeffler's syndrome; interstitial patterns suggest tropical pulmonary eosinophilia) 1
• Pulmonary function tests 1
• High-resolution chest CT 1
• Bronchoscopy with bronchoalveolar lavage (BAL eosinophils >1% support eosinophilic lung disease) 1

Gastrointestinal Assessment (if dysphagia or food impaction)

Upper endoscopy with ≥6 biopsies (2–3 from proximal and 2–3 from distal esophagus) is mandatory for suspected eosinophilic esophagitis. 1, 5

Key points:

• Peripheral eosinophilia is present in only 10–50% of adult eosinophilic esophagitis cases, so normal blood counts do NOT exclude the diagnosis 1, 5
• Diagnosis requires ≥15 eosinophils per high-power field on biopsy 1
• Endoscopic findings: linear furrowing, white exudates, concentric rings, "crêpe-paper" mucosa, strictures 5

Treatment:

• First-line: topical swallowed corticosteroids (fluticasone or budesonide) reduce blood eosinophils in 88% of patients 1, 3
• Maintenance therapy is mandatory after remission due to high relapse rates 1, 3
• Endoscopic dilation for strictures must be combined with anti-inflammatory therapy 1, 3

Neurologic Assessment (if neuropathy suspected)

• Electromyography to confirm eosinophil-induced peripheral neuropathy 1
• Nerve biopsy if EMG consistent with neuropathy 1

Treatment of Specific Helminth Infections

Acute Schistosomiasis (Katayama Syndrome)

• Praziquantel 25 mg/kg three times daily for 2–3 consecutive days 2
• Add prednisolone 20 mg/day for 5 days in acute Katayama syndrome 1
• Repeat praziquantel at 6–8 weeks (eggs and immature worms are treatment-resistant) 2, 3

Strongyloidiasis

• Ivermectin 200 μg/kg daily for 2 days 1
• Critical in immunocompromised patients due to fatal hyperinfection risk 1

Tropical Pulmonary Eosinophilia

• Diethylcarbamazine (DEC) promptly to prevent irreversible pulmonary fibrosis 1
• CRITICAL: Exclude Loa loa and Onchocerca volvulus co-infection first, as DEC causes fatal encephalopathy if Loa loa microfilariae present 1
• Adjunctive prednisolone 20 mg/day for 5 days for ongoing alveolitis 1
• 20% of patients relapse and require second DEC course 1

Loeffler's Syndrome (Ascaris, Hookworm)

• Albendazole 400 mg twice daily for 3 days 1

Common Pitfalls to Avoid

• Do NOT rely on eosinophilia alone to screen for helminth infection—many infected patients have normal eosinophil counts; exposure history must drive testing 2, 1
• Do NOT wait for symptoms before investigating persistent moderate-to-severe eosinophilia—subclinical organ damage may already be present 1
• Do NOT use diethylcarbamazine if Loa loa microfilariae are seen on blood film—use corticosteroids with albendazole first to reduce microfilarial load <1,000/mL 2, 1, 3
• Do NOT diagnose eosinophilic esophagitis based on peripheral eosinophil count alone—tissue biopsy is the gold standard 1, 5
• Do NOT order only one stool specimen—three separate concentrated specimens are required for adequate sensitivity 2, 5, 3
• Do NOT assume seasonal or atopic factors explain counts ≥1.5 × 10⁹/L—comprehensive workup is mandatory 1

Special Populations

Immunocompromised Patients

Urgent evaluation for Strongyloides is mandatory even if asymptomatic, as hyperinfection syndrome carries high mortality. 1 Exclude this infection before initiating any immunosuppressive therapy. 2, 1

Migrants from Endemic Regions

Strongyloides prevalence is high in some migrant populations with asymptomatic eosinophilia; serology is essential even with negative stool microscopy. 2 Schistosoma haematobium is associated with squamous cell bladder carcinoma and requires treatment. 1